CYP3A4 and cancer: Although the interaction of rifampin combined with famitinib in cancer patients in not clear, it is reasonable to assume that concomitant therapy with potent CYP3A4 inducer such as rifamipin may impair the therapeutic properties of famitinib in the treatment of malignant tumors.